



FOSTERING INNOVATION & EXCHANGE



Roche's Commitment to Cardiovascular & Metabolic Disease Discovering What's Next



Obesity is a complex chronic disease with deep clinical and economic impacts. At Roche, we believe transforming health outcomes starts with science, evidence-based care, and a world free from stigma.



cAMP=cyclic adenosine monophosphate, GIP=glucose-dependent insulinotropic polypeptide, GIPR=glucose-dependent insulinotropic polypeptide receptor, GLP-1=glucagon-like peptide 1, GLP-1R=glucagon-like peptide 1 receptor, MOA=mechanism of action, SC=subcutaneous, T2D=type 2 diabetes. 1. Chakravarty MV, et al. Diabetologia. 2023;66:531 (presentation at EASD 2023); 2. Chakravarty MV, et al. Presented at the 60th European Association for the Study of Diabetes Annual Meeting, September 9-13, 2024, Presentation LBA 65; 3. Steenberg S, et al. Presented at the 60th American Diabetes Association Scientific Sessions, June 20-23, 2025, Chicago, IL, USA, Presentation 132-CF; 4. Rodriguez R, et al. Cell Rep Med. 2025;6:102156.

Obesity and Metabolism

Target/MOA	Disease	Route	Phase 1	Phase 2	Phase 3
GLP-1/GIP RA ^{1,2,3,4}	Overweight/Obesity ± T2D	SC (QW)	103 (overweight/obesity) 104 (overweight/obesity + T2D)		ENITH1 (overweight/obesity) ENITH2 (overweight/obesity+T2D)
GLP-1/GIP RA ⁵	T1D + Overweight/Obesity	SC (QD)	OO4		
Anti-latent myostatin Ab ^{6*}	Overweight/Obesity	SC (Q4W)	GYMINDA (Combination with GLP-1/GIP RA)		
GLP-1 ⁷	Overweight/Obesity ± T2D	SC (OD)	201	OW/OB ± T2D	
Long-acting amylin analog ^{8,9}	Overweight/Obesity ± T2D	SC (QW)	ZUPREME-1 trial (overweight/obesity) ZUPREME-2 trial (overweight/obesity + T2D)		
Amylin analog + GLP-1/GIP RA	Overweight/Obesity	SC (QW)			

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Target/MOA	Disease	Route	Phase 1	Phase 2	Phase 3
FGF21 analog ^{10, 11, 12†}	MASH (F2-3;F4)	SC (Q2W)		ENLIVEN	ENLIGHTEN Fibrosis ENLIGHTEN Cirrhosis
anti-TL1A	MASH	SC (Q2,4W)			

Cardiovascular

Target/MOA	Disease	Route	Phase 1	Phase 2	Phase 3
Small Interfering RNA ^{13, 14, 15, 16†}	Hypertension	SC (Q6M)	KARDIA-1, KARDIA-2, KARDIA-3		ZENITH
NLRP3 Inhibitor	ASCVD	SC			



FOR MORE INFORMATION ON OUR TRIALS: Including those for obesity, diabetes, cardiovascular disease and MASH, please contact our Medical Information team at **1-888-762-4388** or scan the QR code below.



*In partnership with Zealand Pharma.
†Pending deal closure.
‡In partnership with Alnylam.
These compounds and/or their uses are investigational. Their safety and efficacy have not been established and they are not authorized for use by any regulatory authority outside the clinical trial setting. Ab=antibody, ASCVD=Atherosclerotic Cardiovascular Disease, FGF21=fibroblast growth factor 21, GIP=glucose-dependent insulinotropic polypeptide, GLP=glucagon-like peptide, NLRP3=NLR family pyrin domain containing 3, QW=once weekly, RA=receptor agonist, T1D=type 1 diabetes, T2D=type 2 diabetes, TL 1A=Tumor Necrosis Factor-like cytokine 1A.
1. ClinicalTrials.gov identifier: NCT06525935; 2. ClinicalTrials.gov identifier: NCT06628362; 3. ClinicalTrials.gov identifier: NCT07351045; 4. ClinicalTrials.gov identifier: NCT07351058; 5. ClinicalTrials.gov identifier: NCT06062069; 6. ClinicalTrials.gov identifier: NCT06965413; 7. ClinicalTrials.gov identifier: NCT05814107; 8. ClinicalTrials.gov identifier: NCT06662539; 9. ClinicalTrials.gov identifier: NCT06926842; 10. ClinicalTrials.gov identifier: NCT04929483; 11. ClinicalTrials.gov identifier: NCT06318169; 12. ClinicalTrials.gov identifier: NCT06419374; 13. ClinicalTrials.gov identifier: NCT04936035; 14. ClinicalTrials.gov identifier: NCT05103332; 15. ClinicalTrials.gov identifier: NCT06272487; 16. ClinicalTrials.gov identifier: NCT07181109. clinicaltrials.gov accessed March 2026.

If you require this information in an accessible format, please contact Roche at 1-800-561-1759.